ArticleThe Journal of investigative dermatology2015
Association with Genetic Variants in the IL-23 and NF-κB Pathways Discriminates between Mild and Severe Psoriasis Skin Disease.
Article in The Journal of investigative dermatology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 50 citations in OpenAlex.
- Association of rs610604 in TNFAIP3 and rs17728338 in TNIP1 gene polymorphisms with psoriasis susceptibility: a meta-analysis of case-control studies.BMC medical genetics · 2020Pooled it
- Mild psoriasis as a suitable model for proof-of-mechanism in a phase 1B setting: Results from a double-blind placebo-controlled trial with guselkumab.British journal of clinical pharmacology · 2025Trial
- Influence of Polymorphisms in the HTR3A and HTR3B Genes on Experimental Pain and the Effect of the 5-HT3 Antagonist Granisetron.PloS one · 2016Trial
- Integrated multi-omics strategies for identifying novel therapies in psoriasis.Bioinformatics (Oxford, England) · 2026Article
- Mendelian randomization reveals DNA methylation-related pyroptosis genes associated with psoriasis risk.Clinical epigenetics · 2026Article
- Genetic liability to psoriasis predicts severe disease outcomes.Genome medicine · 2025Article
- Identification of hub genes for psoriasis and thyroid cancer using bioinformatics analysis.Discover oncology · 2025Article
- A Common Genetic Background for Psoriasis and Cardiovascular Diseases: A Narrative Review.Health science reports · 2025Article
- Integrated Single-Cell and Spatial Transcriptomic Analysis Reveals a Pathological Niche Formed by FAP+ Fibroblasts, Immune, and Endothelial Cells in Psoriatic Lesions.Clinical, cosmetic and investigational dermatology · 2025Article
- Expanding strategies to resolve psoriasis-like inflammation: Non-canonical NF-κB signaling controls IL-23 production in dendritic cells.Molecular therapy : the journal of the American Society of Gene Therapy · 2024Article
- TheInternational journal of molecular sciences · 2023Article
- EULAR study group on 'MHC-I-opathy': identifying disease-overarching mechanisms across disciplines and borders.Annals of the rheumatic diseases · 2023Review
- Biomarkers of disease progression in people with psoriasis: a scoping review.The British journal of dermatology · 2022Article
- Characterization of chromatin accessibility in psoriasis.Frontiers of medicine · 2022Article
- Psoriasis-Associated Inflammatory Conditions Induce IL-23 mRNA Expression in Normal Human Epidermal Keratinocytes.International journal of molecular sciences · 2022Article
- Exploring the Diverse Immune and Genetic Landscape of Psoriatic Arthritis.Journal of clinical medicine · 2021Review
- Long-term Outcomes and Prognosis in New-Onset Psoriasis.JAMA dermatology · 2021Article
- Polymorphisms in the HTR2A and HTR3A Genes Contribute to Pain in TMD Myalgia.Frontiers in oral health · 2021Article
- Apremilast Pharmacogenomics in Russian Patients with Moderate-to-Severe and Severe Psoriasis.Journal of personalized medicine · 2020Article
- TH17/IL23 cytokine gene polymorphisms in bullous pemphigoid.Molecular genetics & genomic medicine · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Psoriasis is clinically heterogeneous, and symptoms can vary from mild almost cosmetic symptoms to severe disease requiring systemic therapy. Biomarkers predicting disease development are lacking. Herein we explored the genetic background in two polarized cohorts of carefully phenotyped patients with long-term follow-up: consistent mild phenotype (n=696) and severe disease course requiring systemic therapy (n=715). All patients were treated at the same dermatology department ensuring homogenous assessment. Genotyping included known psoriasis-associated variants, with special focus on the IL-23 and NF-κB pathways. A case-case study comparing severe and mild psoriasis phenotypes, controlling for age at disease onset and gender, revealed significant differences between the two groups for SNPs in IL23R, NFKB1, IL21, IL12B, NFKBIL1 and IL23A. HLA-C*06 associated equally in the mild and severe disease cohorts. Strong additive effects when combining HLA-C*06 with IL23A, IL23R, IL12B, NFKB1 or TNIP1 were restricted to the severe cohort, indicating that activation of these pathways may influence disease severity in psoriasis. No protective gene was identified in the mild cohort, suggesting that current screens have primarily identified psoriasis variants associated with a more severe phenotype. These results demonstrate the importance of careful phenotyping and long-term clinical follow-up in genetic studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.